Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.8.0.1
Commitments and Contingencies (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 04, 2017
USD ($)
Jun. 29, 2017
USD ($)
Jan. 09, 2017
USD ($)
May 02, 2016
USD ($)
Feb. 28, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
employee
Dec. 31, 2016
USD ($)
Apr. 30, 2012
USD ($)
Loss Contingencies [Line Items]                  
Research and development expense             $ 4,545,000 $ 1,496,000  
Payments to HPI over three-year period       $ 750,000          
Buy-out option payment to HPI       $ 1,000,000          
Licensing agreement term       3 years          
Employee agreement, termination benefits, number of employees | employee             4    
Termination benefits provided to key employees, aggregate amount             $ 1,000,000    
Annamed Agreement                  
Loss Contingencies [Line Items]                  
One-time license documentation fee   $ 40,000              
License agreement, annual maintenance fee   25,000              
Commencement Of Phase II Study For a Licensed Product | IntertechBio Agreement                  
Loss Contingencies [Line Items]                  
Milestone payments liabilities                 $ 200,000
Receipt Of Market Approval For a Licensed Product | Annamed Agreement                  
Loss Contingencies [Line Items]                  
Milestone payments liabilities   225,000              
Receipt Of Market Approval For a Licensed Product | Moleculin Agreement                  
Loss Contingencies [Line Items]                  
Milestone payments liabilities             600,000    
Receipt Of Market Approval For a Licensed Product | IntertechBio Agreement                  
Loss Contingencies [Line Items]                  
Milestone payments liabilities                 500,000
Commencement Of Phase III Study For a Licensed Product | Annamed Agreement                  
Loss Contingencies [Line Items]                  
Milestone payments liabilities   125,000              
Commencement Of Phase III Study For a Licensed Product | Moleculin Agreement                  
Loss Contingencies [Line Items]                  
Milestone payments liabilities             150,000    
Commencement Of Phase III Study For a Licensed Product | IntertechBio Agreement                  
Loss Contingencies [Line Items]                  
Milestone payments liabilities                 250,000
Submission Of First NDA Within United States | Annamed Agreement                  
Loss Contingencies [Line Items]                  
Milestone payments liabilities   $ 175,000              
Submission Of First NDA Within United States | Moleculin Agreement                  
Loss Contingencies [Line Items]                  
Milestone payments liabilities             500,000    
Filing Of a New Drug Application For a Licensed Product | IntertechBio Agreement                  
Loss Contingencies [Line Items]                  
Milestone payments liabilities                 400,000
Houston Pharmaceuticals, Inc                  
Loss Contingencies [Line Items]                  
License fees             225,000 75,000  
MD Anderson                  
Loss Contingencies [Line Items]                  
Payments for research and development agreement $ 346,687   $ 302,500            
Payments for research and development agreement, next twelve months $ 110,000                
Research and development expense             291,687 33,000  
MD Anderson | Annamed Agreement                  
Loss Contingencies [Line Items]                  
License fees             52,500 0  
MD Anderson | Moleculin Agreement                  
Loss Contingencies [Line Items]                  
License fees             85,000 77,500  
MD Anderson | IntertechBio Agreement                  
Loss Contingencies [Line Items]                  
License fees             $ 95,000 $ 75,000  
MD Anderson | IntertechBio Agreement | Servicing Fee payable                  
Loss Contingencies [Line Items]                  
Annual maintenance fee, first anniversary                 10,000
Annual maintenance fee, second anniversary                 20,000
Annual maintenance fee, third anniversary                 40,000
Annual maintenance fee, fourth anniversary                 60,000
Annual maintenance fee, fifth anniversary                 80,000
Annual maintenance fee, sixth anniversary                 100,000
Annual royalty payment, third anniversary following first sale                 600,000
MD Anderson | IntertechBio Agreement | Minimum Annual Royalty                  
Loss Contingencies [Line Items]                  
Annual royalty payment, first anniversary following first sale                 200,000
Annual royalty payment, second anniversary following first sale                 $ 400,000
MD Anderson | Subsequent Event                  
Loss Contingencies [Line Items]                  
Payments for research and development agreement           $ 236,687      
License agreement, annual maintenance fee         $ 10,000        
License agreement, maintenance fee annual increase         5,000        
Minimum royalty payment per year         200,000        
License agreement, maintenance fee - maximum payable per year         $ 50,000        
MD Anderson | Subsequent Event | Minimum                  
Loss Contingencies [Line Items]                  
Royalty on net revenues (as a percent)         3.00%        
MD Anderson | Subsequent Event | Maximum                  
Loss Contingencies [Line Items]                  
Royalty on net revenues (as a percent)         5.00%        
MD Anderson | Subsequent Event | Commencement Of Phase II Study For a Licensed Product                  
Loss Contingencies [Line Items]                  
Additional payments due         $ 150,000        
MD Anderson | Subsequent Event | Submission Of A New Drug Application                  
Loss Contingencies [Line Items]                  
Additional payments due         500,000        
MD Anderson | Subsequent Event | Receipt Of Market Approval For a Licensed Product                  
Loss Contingencies [Line Items]                  
Additional payments due         $ 600,000